Previous 10 | Next 10 |
home / stock / atai / atai articles
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) an...
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares NY Mets owner Steve Cohen has bought as many as 119,092,680 ordinary...
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company ai...
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy...
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Billionaire hedge fund and NY Mets own...
Psychedelics are one of the buzziest topics in tech these days. With entrepreneurs vouching for their benefits for creativity, focus and gener...
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next MAPS Public Benefit Corporation (MAPS PBC), the nonprofi...
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $1...
NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company a...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...